Tuesday, January 30, 2018 10:15 PM ET
Significant Insider Buying Reverses Sale Trend of Last 90 Days in Shares of CRISPR Therapeutics (CRSP)
There was a substantial insider buy in CRISPR Therapeutics shares today as disclosed in a filing with the SEC. One insider — Aktiengesellschaft Bayer, 10% Owner — acquired 527,472 shares in the company having a net market value of approximately $11,999,988. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 65,934 company shares and the sale of 1,305,219 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 711,813 shares and have averaged 316,438 shares per transaction over this time period.
Compared to its peers over the last 90 days, insider buy/sell trading at CRISPR Therapeutics is higher than the 191-company peer group average. Biotechnology & Medical Research peer group saw 168 buy/sell trades during this period for an average of 0.9 transactions per company. The number of shares per buy/sell trade for CRISPR Therapeutics insiders was also higher. Within the peer group there were 11,346,492 shares purchased and 12,354,260 shares sold with company insiders selling 5,999 shares on average.
In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data obtained to compose and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2018 UpTick Data Technologies. All rights reserved.